摘要：中国老年保健协会肺癌专业委员会,陈军,李昕,刘夏,刘东颖,孟庆威,邬麟,徐嵩,徐燕,张琳琳,张新伟,赵洪林.MET 14外显子跳跃突变NSCLC靶向治疗专家共识[J].中国肺癌杂志,2023,26(6):416-428

参考文献：

[1]中国老年保健协会肺癌专业委员会,陈军,李昕,刘夏,刘东颖,孟庆威,邬麟,徐嵩,徐燕,张琳琳,张新伟,赵洪林.MET 14外显子跳跃突变NSCLC靶向治疗专家共识[J].中国肺癌杂志,2023,26(6):416-428

[2]《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》http://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=de66e92b7edd4056ac41c0c4d3c011f3.pdf

[3]Mazieres J, Vioix H, Pfeiffer BM, et al. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clin Lung Cancer. 2023 Sep;24(6):483-497.

[4]Bittoni M, Yang JC, Shih JY, et al. Real-world insights into patients with advanced NSCLC and MET alterations. Lung Cancer. 2021 Sep;159:96-106.

[5]Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018 Oct 1;29(10):2085-2091.

[6]中华医学会病理学分会，国家病理质控中心，中华医学会肿瘤学分会肺癌学组，等. 非小细胞肺癌MET临床检测中国专家共识.中华病理学杂志,2022, 51(11):10.

[7]Wolf J, Hochmair M, Han JY, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 2024 Oct;25(10):1357-1370.

[8]Wu YL, et al. ESMO ASIA. 2022; poster 388.

[9]Baltschukat S, Engstler BS, Huang A, et al. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. Clin Cancer Res. 2019 May 15;25(10):3164-3175.

[10]Grande E, Giovannini M, Marriere E, et al. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study. Br J Clin Pharmacol. 2021 Jul;87(7):2867-2878.

[11]Furqan M, Karanth S, Goyal RK, et al. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncol. Published online April 17, 2024.

[12]Yi-long Wu, et al. Matching-Adjusted Indirect Comparison (MAIC) of overall survival (OS) and treatment related adverse events (TRAE) comparing Capmatinib (CAP) with other Mesenchymal-epithelial transition (MET) Inhibitors for treatment of advanced non-small cell lung cancer (aNSCLC) with MET Exon 14 skipping mutations. 2024 WCLC. EP.12D.05.

[13]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer. Version 1.2025

[14]Owen DH, Ismaila N, Freeman-Daily J, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1. J Clin Oncol. 2024 Jul 10;42(20):e44-e59.

[15]Hendriks LE, Kerr KM, Menis J, et al. Electronic address: clinicalguidelines@esmo.org. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Apr;34(4):339-357.

[16]简明处方：https://www.medlive.cn/recommond.php?kyprojectid=1_002094401_1&hash=DaGO1J

撰写：Cynthia

审校：Felicia

排版：Babel

执行：Aurora

来源：医脉通肿瘤科